查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1727075

診斷用AI:市場考察·競爭情形·市場預測 (2032年)

Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

診斷人工智慧市場按組件（硬體/軟體、服務）、應用（傳染病診斷、放射學、腫瘤學、心臟病學等）、技術（機器學習、自然語言處理等）和地區（北美、歐洲、亞太地區及世界其他地區）細分，預計到 2032 年將維持強勁的複合年增長率。這得益於傳染病和慢性病的增多、數位健康和​​影像技術的日益普及以及全球主要參與者產品開發活動的增加。

2024 年診斷人工智慧市場規模為 16.232 億美元，預計在 2025-2032 年預測期內，複合年增長率將達到 22.31%，到 2032 年將達到 80.8197 億美元。

傳染病和慢性病的盛行率上升正在推動早期精準診斷的需求日益增長，而人工智慧在提高檢測準確性和支援更快的臨床決策方面發揮關鍵作用。同時，數位健康和​​影像技術的日益普及為將人工智慧工具融入現有醫療工作流程奠定了堅實的基礎，從而提高了營運效率和診斷準確性。此外，機器學習的進步和監管機構日益增強的支持力度，促使全球各大公司加強產品開發力度，從而廣泛提供基於人工智慧的診斷解決方案。這些因素共同促成了更準確、更及時、更具可擴展性的醫療服務，預計將在2025-2032年的預測期內推動人工智慧診斷市場的顯著成長。

診斷人工智慧：市場動態

根據世界衛生組織提供的數據，截至2023年，全球估計有3,990萬人感染愛滋病毒（HIV），約有130萬人新感染愛滋病毒。同年，預計約有1,080萬人將罹患結核病（TB）。診斷人工智慧在結核病和愛滋病毒管理中發揮關鍵作用，能夠實現早期發現和高效監測。在結核病領域，人工智慧可以分析胸部X光片和CT掃描影像以識別感染模式，從而減少對放射科醫生的依賴，尤其是在醫療資源匱乏的地區。在愛滋病毒領域，人工智慧有助於追蹤病情進展、預測治療反應並檢測合併感染。這簡化了工作流程，減少了診斷延誤，並使大規模篩檢更容易實施。

此外，全球癌症發生率的上升也是推動診斷人工智慧市場成長的主要因素。癌症診斷涉及複雜的影像分析、病理資訊和基因組數據，使其成為人工智慧應用的理想領域。根據世界衛生組織2024年的數據，2022年全球報告了2,000萬例新增癌症病例，其中肺癌是最常見的癌症類型，佔總數的12.4%，共計250萬例。人工智慧診斷工具能夠偵測人眼透過CT掃描和X光片可能遺漏的細微異常。人工智慧演算法可以分析肺組織中的結節、腫塊和不規則結構，從而實現快速、高精度的診斷。

此外，根據英國心臟基金會（2025年）的數據，全球約有6.4億人患有心臟和循環系統疾病。準確及時地發現這些疾病至關重要，因為早期診斷可以改善預後並降低死亡率。人工智慧工具正越來越多地被整合到診斷過程中，透過分析CT、MRI和超音波心動圖等醫學影像，比傳統方法更準確、更有效率地解讀複雜數據。

數位健康和​​影像診斷技術的廣泛應用也推動了診斷人工智慧市場的發展，因為它提高了醫療診斷的速度、準確性和可近性。人工智慧演算法可以有效分析來自CT、MRI和X光片等的複雜影像數據，有助於腫瘤、循環系統和呼吸系統等領域的早期發現。例如，2024年12月，GE醫療在RSNA 2024大會上發布了其Sonic DL AI MRI演算法，該演算法在腦部、脊椎、骨科和軀幹成像領域實現了高達86%的加速，並提升了影像品質。

本報告調查了全球診斷AI市場，並提供了市場概況、法律和監管環境、市場影響因素分析、市場規模趨勢和預測、各細分市場和地區的詳細分析、競爭格局以及主要公司概況。

本報告提供全球診斷用AI的市場調查，彙整市場概要，法律制度，市場影響因素的分析，市場規模的轉變·預測，各種區分·各地區的詳細分析，競爭情形，主要企業簡介等資訊。

目錄

第1章 診斷用AI:報告簡介

  • 調查範圍
  • 市場區隔
  • 市場估計

第2章 診斷用AI:摘要整理

  • 市場概要

第3章 競爭情形

第4章 法規分析

第5章 診斷用AI:主要要素分析

  • 推動市場要素
    • 傳染病和慢性病發生率不斷上升
    • 數位健康和​​影像技術的採用率不斷提高
    • 主要參與者的產品開發活動不斷增加全球
  • 市場限制與課題
    • 資料隱私與安全
    • 資料品質與數量欠佳
  • 診斷人工智慧：機遇
    • 持續研發罕見疾病及未確診疾病的人工智慧整合技術

第6章 診斷用AI:波特的五力分析

第7章 診斷用AI的評估

  • 各零件
    • 硬體設備/軟體
    • 服務
  • 各用途
    • 感染疾病診斷
    • 放射線
    • 腫瘤
    • 心臟病
    • 其他
  • 各技術
    • 機器學習
    • 自然語言處理
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 全球其他地區

第8章 診斷用AI:企業及產品簡介

  • Aidoc
  • Qure.ai
  • GE HealthCare
  • Siemens Healthineers
  • PathAI
  • Ibex
  • Owkin, Inc
  • Imagen Technologies
  • Aiforia
  • RADLogics
  • Terarecon, Inc.
  • Prenosis, Inc.
  • Ibex
  • Google LLC
  • GE HealthCare
  • DreaMed
  • Riverain Technologies
  • Terarecon, Inc.
  • Aiforia
  • RADLogics

第9章 KOL的見解

第10章 計劃方法

第11章 關於DelveInsight

第12章 免責聲明·聯絡方式

Product Code: DIMDCL0864

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of infectious and chronic diseases, growing adoption of digital health & imaging technologies, increase in product development activities among the key market players across the globe.

The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032. The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe fueled by advancements in machine learning and growing regulatory support are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Diagnostics Market Dynamics:

According to the data provided by the World Health Organization, in 2023, globally, an estimated 39.9 million people were living with HIV and approximately 1.3 million population acquired HIV. Additionally, as per the same source, in 2023, approximately 10.8 million people fell ill with tuberculosis (TB). Artificial Intelligence (AI) in Diagnostics is boosting the management of TB and HIV by enabling early detection and efficient monitoring. In TB, AI analyzes chest X-rays and CT scans to identify infection patterns, reducing reliance on radiologists, especially in low-resource areas. For HIV, AI supports disease progression tracking, treatment prediction, and detection of co-infections. These capabilities streamline workflows, reduce diagnostic delays, and enhance large-scale screening efforts.

Moreover, the rising global incidence of cancer is a major factor driving the growth of Artificial Intelligence (AI) in Diagnostics market. Cancer diagnosis often involves complex imaging, pathology, and genomic data, making it an ideal application for artificial intelligence. According, to the data provided by the World Health Organization (2024), in 2022, globally, there were an estimated 20 million new cancer cases with lung cancer being the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases. AI-powered diagnostic tools, particularly those using CT scans and X-rays, are capable of detecting subtle signs of lung cancer that might be missed by the human eye. AI algorithms analyze imaging data to identify nodules, masses, and irregularities in lung tissues, allowing for quicker and more accurate detection.

In addition, according to data provided by the British Heart Foundation (2025), globally, around 640 million people were living with heart and circulatory diseases across the world. These diseases require precise and timely detection, as early diagnosis can greatly improve outcomes and reduce mortality rates. AI tools are increasingly being integrated into the diagnostic workflow to analyze medical imaging (e.g., CT, MRI, echocardiograms) and interpret complex data with higher accuracy and efficiency than traditional methods thereby escalating the overall market of Artificial Intelligence (AI) in Diagnostics.

Furthermore, the growing adoption of digital health and imaging technologies is boosting the AI diagnostics market by improving the speed, accuracy, and accessibility of medical diagnoses. AI algorithms efficiently analyze complex imaging data from CT scans, MRIs, and X-rays, aiding early detection in fields like oncology, cardiology, and pulmonology. For instance, in December 2024, GE HealthCare's Sonic DL AI MRI algorithm, launched at the RSNA 2024 conference, accelerates scans by up to 86% while enhancing image resolution for brain, spine, orthopedic, and body imaging.

Together, the above-mentioned factors are expected to boost the overall market of Artificial Intelligence (AI) in Diagnostics.

Despite these promising growth factors, the Artificial Intelligence (AI) in Diagnostics market faces challenges such as data privacy & security. Additionally, AI algorithms require large, high-quality datasets to train effectively, and integrating with existing healthcare systems can be challenging which may hinder the future market of Artificial Intelligence (AI) in Diagnostics during the forecast period.

Artificial Intelligence (AI) in Diagnostics Market Segment Analysis:

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the component segment of the Artificial Intelligence (AI) in Diagnostics market, the software category is projected to capture a significant revenue share in 2024. Software solutions are playing a pivotal role in boosting the overall market of Artificial Intelligence (AI) in Diagnostics by significantly enhancing the capabilities of diagnostic tools, improving accuracy, and streamlining clinical workflows.

These software systems integrate AI algorithms with various medical devices, such as imaging machines (CT scans, MRIs, X-rays), laboratory testing equipment, and patient monitoring systems, enabling real-time analysis and interpretation of complex data. AI-powered diagnostic software can process large volumes of data rapidly, identifying patterns and anomalies that human clinicians might miss. For instance, in imaging, AI software helps detect early signs of diseases such as cancer, cardiovascular conditions, and neurological disorders by analyzing medical images for subtle irregularities that may not be visible to the naked eye. In pathology, AI software assists in the classification and grading of tumors or detecting abnormalities in tissue samples, which aids in accurate diagnosis and treatment planning.

Moreover, software innovations are driving advancements in personalized medicine by analyzing patient data to predict disease progression, identify the most effective treatment plans, and monitor ongoing responses to treatment. This capability is particularly valuable in chronic disease management, such as in diabetes, heart disease, and oncology, where continuous monitoring is essential for adjusting treatments and preventing complications. The automation provided by AI software also helps reduce diagnostic errors, minimize human workload, and enhance the efficiency of healthcare professionals, allowing them to focus more on patient care rather than time-consuming manual tasks. Furthermore, the integration of AI diagnostic software with electronic health records (EHRs) enables seamless data sharing across different healthcare systems, improving collaboration among specialists and ensuring more coordinated care. The growing availability of cloud-based AI diagnostic software solutions further supports scalability, making advanced diagnostic tools more accessible to healthcare providers, especially in underserved or resource-limited regions. As more software solutions are developed and validated, the AI diagnostics market is experiencing rapid growth.

Additionally, the increase in product development activities such as product launches and product approvals are further escalating the overall market. For instance, in July 2024, Tempus received FDA 510(k) clearance for its ECG-AF algorithm, an AI-based tool designed to identify patients at increased risk of atrial fibrillation (AFib). ECG-AF is the first of a suite of next-generation diagnostics that Tempus has designed to identify patients at risk for a variety of cardiovascular conditions.

Given these factors, the software segment is expected to witness robust growth during the forecast period, thereby driving the overall expansion of Artificial Intelligence (AI) in Diagnostics market.

North America is expected to dominate the overall Artificial Intelligence (AI) in Diagnostics market:

North America is projected to account for the largest share of Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

According to the data provided by the International Agency for Research on Cancer, in 2022, the estimated number of new cases of brain cancer was 24,940 and the projections were estimated to increase 31,278 cases by 2045. AI technologies, particularly those used in medical imaging like MRI and CT scans, play a crucial role in identifying brain tumors, pinpointing their exact location, and assessing their size and characteristics with high precision. AI algorithms can analyze complex brain scans faster and with greater accuracy than traditional methods, detecting even subtle signs of tumors that might be missed by human radiologists thereby escalating the need for Artificial Intelligence (AI) in Diagnostics across the region.

According to the data provided by the Government of Canada, in 2022, there were, 13,953 cases of syphilis were reported in Canada, marking an 11% increase from 2021. AI-powered diagnostic systems, such as those integrating machine learning with laboratory testing and imaging, can improve the speed and accuracy of syphilis detection. AI algorithms can analyze large datasets of medical images (such as syphilis-related lesions in oral, genital, or anal regions) and blood tests (like serologic tests), identifying subtle patterns or abnormalities that may be difficult to detect manually.

Additionally, the region benefits from ongoing advancements in Artificial Intelligence (AI) in Diagnostics -related R&D, product launches, and regulatory approvals. Such developments further accelerate market expansion. For instance, in October 2024, Owkin introduced MSIntuit(R) CRC v2, a next-generation AI diagnostic tool to improve colorectal cancer (CRC) detection.

In summary, the combination of a high disease burden, innovative R&D landscape, advanced healthcare infrastructure, and favorable regulatory policies makes North America a leading market for AI in Diagnostic market throughout the forecast period.

Artificial Intelligence (AI) in Diagnostics Key Players:

Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

Recent Developmental Activities in the Artificial Intelligence (AI) in Diagnostics Market:

  • In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, introduced the latest advancements in its innovative product platform, Ibex-AI. These new features, developed in collaboration with expert pathologists worldwide who actively use the platform in routine clinical practice, highlight Ibex's ongoing commitment to creating cutting-edge diagnostic tools tailored to the needs of healthcare professionals on the frontlines of patient care.
  • In October 2023, Lucida Medical Ltd, announced that it received Class IIb CE certification for its AI-powered prostate cancer detection software, Prostate IntelligenceTM (PiTM) Leveraging advanced AI technology, PiTM analyzes MRI scans and is seamlessly integrated into the radiologist's workflow.
  • In March 2023, Qritive launched its latest AI-driven innovation QAi Prostate, designed specifically for prostate cancer diagnosis. Utilizing cutting-edge machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision.

Key Takeaways from the Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Market size analysis for current Artificial Intelligence (AI) in Diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in Diagnostics market.
  • Various opportunities available for the other competitors in Artificial Intelligence (AI) in Diagnostics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Artificial Intelligence (AI) in Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in Diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Artificial Intelligence (AI) in Diagnostics product providers
  • Research organizations and consulting companies
  • Artificial Intelligence (AI) in Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Artificial Intelligence (AI) in Diagnostics
  • Various end-users who want to know more about the Artificial Intelligence (AI) in Diagnostics market and the latest technological developments in the Artificial Intelligence (AI) in Diagnostics market.

Frequently Asked Questions for the Artificial Intelligence (AI) in Diagnostics Market:

1. What is Artificial Intelligence (AI) in Diagnostics?

  • Artificial Intelligence (AI) in Diagnostics refers to the use of artificial intelligence technologies, such as machine learning and deep learning algorithms, to analyze medical data (such as images, lab results, or patient records) to assist in diagnosing diseases and conditions. AI can enhance diagnostic accuracy, speed, and efficiency by detecting patterns or abnormalities that might be overlooked by human clinicians. It is widely used in areas like medical imaging, pathology, genomics, and disease monitoring, helping healthcare professionals make more informed decisions and improve patient outcomes.

2. What is the market for Artificial Intelligence (AI) in Diagnostics?

  • The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032.

3. What are the drivers for the global Artificial Intelligence (AI) in Diagnostics market?

  • The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe-fueled by advancements in machine learning and growing regulatory support-are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Artificial Intelligence (AI) in Diagnostics market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

5. Which region has the highest share in the global Artificial Intelligence (AI) in Diagnostics market?

  • North America is projected to account for the largest share of the Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

Table of Contents

1. Artificial Intelligence (AI) in Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Artificial Intelligence (AI) in Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

5. Artificial Intelligence (AI) in Diagnostics Market Key Factors Analysis

  • 5.1. Artificial Intelligence (AI) in Diagnostics Market Drivers
    • 5.1.1. Rising cases of infectious and chronic diseases
    • 5.1.2. Growing adoption of digital health & imaging technologies
    • 5.1.3. Increase in product development activities among the key market players across the globe
  • 5.2. Artificial Intelligence (AI) in Diagnostics Market Restraints and Challenges
    • 5.2.1. Data privacy and security
    • 5.2.2. Low data quality and quantity
  • 5.3. Artificial Intelligence (AI) in Diagnostics Market Opportunities
    • 5.3.1. Ongoing research and development in integrating AI for rare and undiagnosed diseases

6. Artificial Intelligence (AI) in Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Artificial Intelligence (AI) in Diagnostics Market Assessment

  • 7.1. By Component
    • 7.1.1. Hardware/Software
    • 7.1.2. Services
  • 7.2. By Application
    • 7.2.1. Infectious Disease Diagnostics
    • 7.2.2. Radiology
    • 7.2.3. Oncology
    • 7.2.4. Cardiology
    • 7.2.5. Others
  • 7.3. By Technology
    • 7.3.1. Machine Learning
    • 7.3.2. Natural Language Processing
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.3. India Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)

8. Artificial Intelligence (AI) in Diagnostics Market Company and Product Profiles

  • 8.1. Aidoc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Qure.ai
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GE HealthCare
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Siemens Healthineers
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. PathAI
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Ibex
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Owkin, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Imagen Technologies
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Aiforia
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. RADLogics
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Terarecon, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Prenosis, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Ibex
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Google LLC
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. GE HealthCare
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. DreaMed
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Riverain Technologies
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Terarecon, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Aiforia
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. RADLogics
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Figure 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Figure 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Figure 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Figure 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Figure 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Figure 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Figure 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Figure 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Figure 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Figure 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Figure 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Figure 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Figure 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Figure 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Figure 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Figure 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Figure 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Figure 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Figure 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Figure 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Figure 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Figure 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Figure 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Figure 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Figure 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis